<DOC>
	<DOC>NCT01061359</DOC>
	<brief_summary>Evaluation of efficacy of treatment with epirubicin (5 years follow-up). Evaluation of frequency of dose reduction. Evaluation of frequency of neoadjuvant treatment with E(120mg) / C(600mg). Evaluation of unexpected and serious adverse events. (E=Epirubicin; C =Cyclophosphamide)</brief_summary>
	<brief_title>Application Of Epirubicin Within A Neo-/Adjuvant Chemotherapy In Patients With Primary Breast Cancer</brief_title>
	<detailed_description>Postmarketing surveillance study. Non-Probability Sample</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Pre and postmenopausal female patients with histologically confirmed primary breast cancer Metastatic breast cancer, locally advanced or recurrent breast cancer, previous cancer history</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Neoadjuvant Treatment</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Adjuvant</keyword>
	<keyword>Epirubicin</keyword>
</DOC>